Desensitizing mice to ovalbumin through subcutaneous microsphere immunotherapy (SMITH)

Reisacher, William R.; Liotta, Dara; Yazdi, Sara; Putnam, David

doi:10.1002/alr.20074

Cited by 4 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although there have been few studies investigating OIT for food allergy in murine models, almost none have addressed long-term protection after stopping therapy. 40,[45][46][47] In a report by Leonard et al, 39 OIT of ovalbumin-sensitized mice resulted in protective desensitization when the antigen was presented through the gastrointestinal mucosa but not injected systemically, and protective effects were lost 2 weeks after therapy was discontinued. These results are consistent with recent clinical results in which the majority of patients undergoing peanut immunotherapy regained reactivity after discontinuing treatment.…”

Section: Discussionmentioning

confidence: 99%

Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy

Srivastava

Siefert

Fahmy

et al. 2016

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy

Srivastava

Siefert

Fahmy

et al. 2016

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…They can modulate the immune response with fewer side effects. It was demonstrated that recombinant birch pollen coated with PLGA (polylactic-co-glycolic acid) nanoparticles regulated the ongoing T2 cell response after a single dose ( 649 , 650 ).…”

Section: Treatment Of Allergic Rhinitismentioning

confidence: 99%

Turkish Guidelines for Diagnosis and Treatment of Allergic Rhinitis (ART)

Ecevit¹,

Özcan²,

Can³

et al. 2021

TAO

View full text Add to dashboard Cite

Object: To prepare a national guideline for Otorhinolaryngologist who treat allergic rhinitis patients. Methods: The study was conducted by three authors, namely the writing support team. The support team made the study plan, determined the writing instructions, chose the subgroups including the advisory committee, the advisors for authors and the authors. A workshop was organized at the very beginning to explain the details of the study to the team. Advisors took the chance to meet their coworkers in their subgroups and determined the main headings and subheadings of the guideline, together with the authors. After key words were determined by the authors, literature search was done in various databases. The authors keep in touch with the advisors and the advisors with the advisory committee and the support group at every stage of the study. National and International published articles as well as the abstracts of unpublished studies, imperatively presented in National Congresses, were included in this guideline. Only Guideline and meta-analyses published in last seven years (2013-2017) and randomized controlled studies published in last two years (2015-2017) were included. After all work was completed by the subgroups, support team brought all work together and edited the article. Results: A detailed guideline about all aspects of allergic rhinitis was created. Conclusion: The authors believe that this guideline will enable a compact and up-to-date information on allergic rhinitis to healthcare professionals. This guideline is the first in the field of Otolaryngology in Turkey. It should be updated at regular intervals.

show abstract

“…Thus far, studies have been limited to allergen-sensitized murine models, but the types of nanoparticles available and allergen targets continue to increase [52].…”

Section: Nanoparticlesmentioning

confidence: 99%

New advances in allergy immunotherapy

Reisacher

Schwanke²

2016

Current Opinion in Otolaryngology & Head and Neck Surgery

Self Cite

View full text Add to dashboard Cite

show abstract

Desensitizing mice to ovalbumin through subcutaneous microsphere immunotherapy (SMITH)

Abstract: Our data suggest that SMITH has the ability to downregulate the production of antigen-specific IgE in a food allergy model, and this observation in our study was not dose-dependent. Its potential use in the treatment of IgE-mediated allergic disease warrants further investigation.

Cited by 4 publications

References 28 publications

Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy

Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy

Turkish Guidelines for Diagnosis and Treatment of Allergic Rhinitis (ART)

New advances in allergy immunotherapy

Contact Info

Product

Resources

About